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ABSTRACT

Phoslactomycins (PLMs) are a group of natural products belonging to a polyketides class.
These polyketides are synthesized by sequential reaction catalyzed by a collection of
enzymes activities called polyketide synthases. A polyketide is a large class of diverse
compounds that are characterized by more than two carbonyl groups connected by single
intervening carbon atoms. In other words, a polyketide is a polymer whose monomer is a
ketide. The PLMs are also known as phosphazomycins or phospholines. These compounds
were isolated based on antifungal and antitumor activities. This array of promising
biological activities has stimulated research into the field of PLMs for treatment of various
diseases such as aspergillosis. A significant success has been reported in understanding and
manipulating PLM biosynthesis. However, its post-polyketide biosynthetic mechanism
remains to be elucidated. In this study, we established steps needed to pave the way for the
elucidation of the post-polyketide synthase tailoring steps in the phoslactomycin
biosynthetic pathway. Various, biological activities of polyketide natural products are often
linked with specific structural motifs, biosynthetically introduced after construction of the
polyketide core. Therefore, investigation of such “post-polyketide synthase (PKS)”
modifications is important, and the accumulated knowledge on these processes can be
applied for combinatorial biosynthesis to generate new polyketide derivatives with
enhanced biological activity.
In this study, the enzymes and genes responsible for the modification of the
phoslactomycin moiety have been investigated to verify their functions and to study how
i

they are coordinated to achieve the desired phoslactomycin. The proposed modification
steps in the PLM biosynthesis pathway involves, PlmT4 a cytochrome P450
monooxygenase, PlmT5, a kinase, and PlmT8 an oxidoreductase. These enzymes were
successfully cloned, overexpressed, and purified from an overexpression vector. Mutant
strains for two genes plmT4 and plmT8 were either constructed or studied. The function of
PlmT4 tailoring enzyme was characterized, by gene disruption and an in vitro enzyme
activity assay. The isolation of PLM 1 an intermediate analog from plmT4 mutant strain
and the observation of a malonylated PLMs, suggests that the malonyl side chain is
introduced during polyketide chain formation These results, will pave the way to delineate
the intermediary steps between the PLM PKS product(s) that is released from the PLM
PKS and the formation of the final phoslactomycin.
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CHAPTER 1. INTRODUCTION

1.1 BACKGROUND

The discovery of penicillin in the 1920s followed by its successful application to treat
infectious diseases, brought a lot of interest in finding new antibiotics from natural products
1, 2

. Meaningful progress has been made in both academia and industry leading to the

isolation of thousands of novel natural products from a variety of sources including plants,
insects, bacteria, fungi, and marine organisms3,4. However, serious infections caused by
bacteria that have become resistant to commonly used antibiotic have become one of the
most serious healthcare problems in the 21st century1. The emerging drug resistant
pathogens demands novel antibiotics classes to be developed5. Among many natural
products, polyketides are not only the most promising ones for developing new antibiotic
leads, but also exhibit unusually high therapeutic value ranging from clinical use as
anticancer, antiviral, and immunosuppressant drugs6,7. Figure 1 shows a representative of
polyketide natural products that possess pharmacologically useful properties and have
clinical uses.

1

Figure 1. Examples of some commonly used polyketide derived antibiotics

1.2 POLYKETIDES

Polyketides, isolated mostly from bacterial and fungal species, comprises one of the most
structurally diverse classes of natural products whose scaffolds include macrolides,
polyethers, enediynes, polyphenols, and others8, 9. Polyketides are produced as secondary
metabolites and they display a wide range of pharmaceutical properties10. Figure 1 shows
examples of polyketides that have therapeutic value such as rapamycin, an
2

immunosuppressant, lovastatin, a cholesterol lowering agent and resveratrol, a
chemopreventive. Since their discovery, a number of polyketides have been clinically
approved as drugs, in fact polyketide-derived pharmaceuticals comprise 20% of the topselling drugs in the world11, 12. There are 10,000 known natural polyketides, and about 1%
has useful biological activities11. There is a tremendous interest in discovering new of
polyketide with improved or novel pharmacological properties. Synthetic organic
chemistry, molecular genetics and biochemistry are common routes utilized to access or
obtain new analogues. However, synthesis of polyketides remains problematic, due to the
structural complexity of polyketides with many functional group and stereo chemical
centers6. Polyketides can also be difficult to isolate naturally since the producing organisms
are often hard to culture and produce low yields6,

12

. However, significant advances in

microbial genetics and biochemistry during the past decades has permitted a better
understanding of

the functions of

genes involved in polyketide biosynthesis13.

Understanding the pathway provides the necessary knowledge for manipulating these
natural enzyme systems to produce novel metabolites.
1.3 BIOSYNTHESIS OF THE POLYKETIDE BACKBONE

Polyketides are assembled by enzymes known as polyketide synthases14. Polyketides
synthases (PKSs) are currently classified into three broad types based on the protein
architecture and biosynthetic schemes14. These are type 1, type 11 and type 11115. The ﬁrst
reports of bacterial type I PKS was in 1990, for type II PKS was in 1984 and type III PKS
in 199916. Type I PKS are large multifunctional enzymes, which are organized into
3

modules15. Modular PKS are demonstrated by 6-deoxyerythromycin B synthase (DEBS)
16 for the biosynthesis of reduced polyketides such as erythromycin as seen in Figure 2 17.
Each separate module contains three domains to catalyze one cycle of chain extension,
ketosynthase (KS), acyltransferase (AT), and acyl carrier protein (ACP). Some modules
carry variable domains, such as ketoreductase (KR), dehydratase (DH) and enoylreductase
(ER), which are responsible for keto group modification18. Type II PKS are discrete
dissociable proteins which only own one enzymatic activity or domain, respectively14. The
discrete proteins work synergistically and can be used iteratively, thus the final product
cannot be predicted. Type III PKS are simple homodimers of ketosynthases which catalyze
the condensation of one to several molecules of extender substrate onto a starter substrate
iteratively13, 18. Bacterial and fungal PKS genes have been found to exist as gene clusters19.
The chemistry associated with PKSs is closely related to that of the well-studied fatty acid
synthases (FASs)19. Polyketide biosynthesis overlaps with fatty acid synthesis not only in
terms of mechanistic details involved in chain elongation process but also in that both the
utilize common precursors such as acetyl coenzyme A (CoA), and malonyl CoA

20

.

Products synthesized by various types of PKSs can undergo different sets of post-PKS
modifications by decorative enzymes encoded in the biosynthetic pathway21, 22.

4

Figure 2. Structural organization of a bacterial type 1 PKS

1.4 POST-PKS MODIFICATIONS AND SIGNIFICANCE OF POST-PKS
MODIFICATIONS

The formation of a biologically active polyketide requires that fully condensed products of
PKS catalyzed reactions usually undergo a series of tailoring events known as post-PKS
events such as glycosylation, methylation, oxidation, reduction, and halogenation23. Such
tailoring can enormously change the pharmacological properties of the parent polyketides,
impacting factors such as solubility or receptor binding ability of the modified parent
compound24. Post-PKS modification has been the subject of intense investigations over the
past two decades and proved as a rich source of intriguing and unprecedented enzyme
chemistries. As mentioned earlier, these post-PKS events usually result in the conversion
of a biologically non-active polyketide into an active product25. For example, Figure 3
showing the conversion of inactive 6-deoxyerythronolide B, to potent antibacterial agent,
erythromycin A.

5

Erythromycin A is synthesized in two phases. ability to manipulate natural.The first phase
involves the PKS portion of the molecule, and the second is post polyketide
synthase “tailoring”. The systems to produce novel metabolites rests largely on increased
mechanistic understanding of how these molecules are generated in the first and second
phase.

Figure 3. Post-tailoring steps leading to formation of erythromycin
Tailoring enzymes such as oxidoreductases, group transferases, halogenases,

and

deoxysugar biosynthetic enzymes have been largely used to generate modified polyketides,
occasionally with improved pharmacological properties8. The overall objective of this work
was to focus on initial post-PKS modifications involved in the biosynthesis of
phoslactomycin polyketide.
6

1.5 PHOSLACTOMYCIN BIOSYTHESIS

Phoslactomycins (PLMs) are polyketide natural products and are produced by several
Streptomyces species. Streptomyces sp. HK803 is reported to produce six analogues of
phoslactomycin (Plm A through F), shown in Figure 4 23. PLMs were isolated based on
their potent antifungal activities. The protein phosphatase 2A (PP2A) inhibition is believed
to be the mechanism of action and the basis for this antifungal activity26. A significant
success has been reported in understanding and manipulating PLM biosynthesis. The
biosynthesis of PLMs is catalyzed by modular polyketide synthase as shown in Figure 5.
It has been reported and verified that it uses cyclohexanecarboxylic acid (CHC) as a starter
unit27. However, some of the biosynthesis steps of the post-polyketide synthase tailoring
steps of PLMs remain to be elucidated.
The gene cluster for phoslactomycin has been cloned and characterized. The sequence
analysis revealed a 75kb region containing 29 open reading frames that appear to be
associated with PLM biosynthesis28. Enzymes proposed to be involved in post polyketide
modification studied so far are, PlmT2, PlmS3 and PlmS2. This work has led to the
discoveries that the ∆2, 3 double bond of the unsaturated lactone is established by a post
tailoring enzyme PlmT221. This is because the mutant strain named NP7 (plmT2∆plmS2)
was shown to produce C-3 malonylated PLM B (M-PLM B) The enzyme PlmT2 is thought
to catalyze an unprecedented decarboxylative elimination reaction in the PLM intermediate
with a malonylated group at C-3 as shown in Figure 6 , even though up to this date it
remains to be determined at which stage the decarboxylation occurs21. This observation
7

demonstrates that all modification steps which occur to the PLM core structure can occur
with a C-3 malonyl ester. Thus it is possible to observe malonylation as we study the post
polyketide synthase -tailoring steps in the PLM biosynthetic pathway.

Figure 4. Structure of Phoslactomycin
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Figure 5. Type 1 Phoslactomycin PKS
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Figure 6. Possible role for PlmT2 in catalyzing a decarboxylative elimination

Studies on the biosynthetic pathway of Streptomyces pulveraceus which produces
fostriecin antibiotics which are structurally related to PLMs also indicated that malonylated
9

polyketide formation could be a normal biosynthetic process in the formation of
unsaturated lactone in fostriecin25. Studies on other post-polyketide synthase tailoring
enzymes involved in the PLM pathway, PlmS2 and PlmS3 also revealed some information
regarding post polyketide synthase tailoring steps. A mutant strain of the gene, plmS2,
resulted in a mutant (NP2) that only produced PLM B29. Additionally, the plmS2 open
reading frame (ORF) was expressed as an N-terminally polyhistidine-tagged protein in
Streptomyces coelicolor and the purified protein has been shown to catalyze conversion of
PLM B to PLM G as shown in Figure 729 . Data obtained demonstrated that PlmS2, a
cytochrome P-450 monooxygenase (CYPs), is responsible for catalyzing hydroxylation at
C-18 of the PLM B as shown in Figure 7. F). The plmS3 gene was identified as the
acyltransferase responsible for C-18 acylation of PLM G13 . This was confirmed by
generation of a plmS3 deletion mutant that resulted in selective production of PLM G,
supporting the proposed role of this gene product. The 921-bp plmS3 ORF was cloned and
expressed as an N-terminally polyhistidine-tagged protein in E.coli, and the recombinant
purified protein was shown to catalyze acylation of PLM G with isobutyryl-CoA, 3methylbutyryl-CoA and cyclohexyl-carbonyl-CoA to give PLM A, PLM C and PLM E
respectively, also confirming the role of plmS3 gene product13.
This work will focus on studying other post-polyketide synthase tailoring genes, plmT4
(cytochrome P450 monooxygenase), plmT5 (a kinase), and plmT8 (oxidoreductase). Figure
9 shows the focus for this work, it is noteworthy that the introduction of amine precedes a
reaction by an oxidoreductase, to form an aldehyde that will then be converted to an amine

10

by a proposed aminotransferase PlmT1. This project will pave the way towards deciphering
the post polyketide synthase tailoring steps in the phoslactomycin biosynthesis pathway.

Figure 7. The last two steps of the phoslactomycin biosynthetic pathway

11

.

C-9 (Phosphorylation)

C-8 (hydroxylation)

C-25 amine

Figure 8. The proposed post-polyketide tailoring steps in the phoslactomycin
biosynthetic pathway, studied for this project
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CHAPTER 2. ISOLATION AND PARTIAL CHARACTERIZATION OF PLM 1

2.0 INTRODUCTION

In nature phoslactomycins are synthesized by modular PLM polyketide synthases and then
modified by post-PKS enzymes28, 29. As mentioned earlier, the PLM gene cluster has been
cloned and on the basis of predicted functions for each post-PKS gene inferred from
sequence similarities, it was proposed that the post tailoring steps of the phoslactomycin
biosynthesis pathway follow the pathway shown in Figure 9, but confirmation of the
proposed pathway is unknown28. In order to pave the way for the elucidation of the ordering
steps of the post-polyketide synthase tailoring steps in the phoslactomycins pathway, we
decided to study the functional role of the first proposed gene involved in the postpolyketide synthase tailoring steps in vivo.
Targeted gene replacement of post-PKS genes, provides a very useful tool for elucidation
of the biosynthetic pathway, by analysis of accumulated intermediates or shunt products.
Acquired knowledge from isolating and characterizing pathway intermediates can also be
used in context of combinatorial biosynthesis to generate new unnatural natural products
with potentially higher or altered biological activities30. A good example is the CYP450
monooxygenase EpoK that catalyzes the final epoxidation step in epothilone A and B
biosynthesis. Upon deletion of epoK, the resulting mutant stain accumulates epothilones C
and D with epothilone D being most valuable antitumor due to increased therapeutic
index31. It is possible that the opposite phenomenon can be observed, for example
13

biosynthesis gene inactivation in mithramycin, where gene inactivation led to the
production of biologically inactive precursor premithramycin32.
This chapter describes the isolation and partial structural elucidation of a new
phoslactomycin intermediate (PLM 1) isolated from the culture broth of a plmT4 gene
replacement mutant strain (named NP5) made from a mutant strain named NP2 (plmS2
gene replacement mutant) a PLM B producing strain29. We report that in vivo plmT4 gene
replacement leads to the accumulation of PLM 1, the earliest intermediate released from
the phoslactomycin biosynthesis assembly line, supporting the proposed pathway in Figure
9. PLM 1 was purified from various fractions by reverse phase HPLC to yield 0.12mg 1mg and was partially characterized using a combination of spectroscopic analyses (MS,
LC-MS and NMR) and the data obtained was consisted with the formation of the predicted
PLM 1 compound.

Figure 9. Proposed ordering of the post PKS tailoring steps in the PLM pathway
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2.1 MATERIALS AND METHODS

2.1.1Materials

All chemicals and solvents were purchased from Sigma or Fisher and were of highest grade.
Yeast extract, N-Z amine type A and beef extract were obtained from Difco. Yeast was
generously given as a gift from Eli Lilly Scientific. Luria-Bertani (LB) capsules were
purchased from Research Products International.
2.1.2 Strain and Culture Conditions

The NP2 mutant (∆plmS2, the control used as wild type) and the NP5 (∆plmT4∆plmS2)
mutants were generated by Nadaraj Palaniappan using a gene deletion method. The strain
was maintained on SY agar (1.0% soluble starch, 0.1% yeast extract, 0.1% N, Z Amine
type A, (pH 7.0) for 7-14 days until the colonies appeared grayish in color. A seed culture
was then prepared by inoculating 50mL of seed medium (3.0% soluble starch, 1.0% dried
yeast, 0.3% NaCl, 0.3% CaCO3, pH 7.0) in a 500mL baffled flask with a loopful of spores.
This culture was incubated at 28°C in the dark with shaking at 170 rpm for 48hrs. A second
culture was then started using 1-1.5mL of the seed culture in 70mL of production medium
(3.0% soluble starch, 1.0% dried yeast, 0.3% NaCl, 0.1% meat extract, 0.3% CaCO3, pH
7.0) in a 500mL baffled flask and was incubated for 96 hours at 28°C in the dark with
shaking at 170 rpm. To enhance production of naturally occurring PLMs or promote the
production of novel compounds, the carboxylic acid form of the corresponding starter units

15

(cyclohexanecarboxylic acid 8-10mg per day )was dissolved in ethanol and were added to
the production medium in four equal portions at 0, 24, 48 and 72 hours. At the end of the
fermentation period, the mycelia were removed by centrifugation and the supernatant was
subjected to further analysis and purification.
2.1.3 Equipment

Analytical and semi-preparative HPLC were performed using an Agilent 1100 HPLC
system connected to a diode array detector. Samples were injected onto a 5µm Discovery
HS C18 reverse phase column (4.6 x 250 mm, Supelco, Belefonte, PA) using a linear
gradient from 0% to 60% between solvent A (acetonitrile: water; 20:80 with 0.05% formic
acid) and solvent B (acetonitrile: water; 80:20 with 0.05% formic acid) over 40 minutes at
a flow rate of 1.0 ml/min and detected at 235nm. Semi-preparative HPLC was performed
using a 5µm Phenomenex C18 column (10.0 x 250 mm) under the same conditions except
with a flow rate of 3.0 ml/min. Preparative HPLC was conducted with an Ascentis C18
preparative column (Supelco, Belefonte, PA). Mass spectrometric analysis was carried out
with a mass spectrometer (Bruker, Billerica, MA) utilizing electrospray ionization (ESI).
4.0. LC-MS analysis was carried out using a linear gradient between solvent A (100%
water, 0.1% formic acid) and solvent B (acetonitrile, 0.1% formic acid) from 20 to 60%
over 30 minutes at a flow rate of 0.3 ml/min using an Agilent 1200 series HPLC equipped
with an autosampler. The column used was a 5µm Discovery HS C18 reverse phase column
(2.1 x 250 mm). All constant temperature incubations were done using an Innova 44
incubator (±0.5°C, New Brunswick Scientific, Edison, NJ).
16

2.1.4 Analysis of NP5 Fermentation Broth

To verify the presence of PLM products in the supernatant after fermentation, the
fermentation broth was centrifuged and filtered (0.2 µL PTFE filter, Millipore Corp, MA).
500µL of filtered broth was analyzed by analytical HPLC and PLM products were
identified based on known retention times. The broth was injected onto a 5 μM Discovery
HS C18 reverse phase column (4.6 x 250 mm, Supelco, Belefonte, PA) using a linear
gradient described above and UV detection at 235 nm.
2.1.5 Isolation and Purification of PLM 1

Once production was confirmed, PLM products were extracted using XAD4 hydrophobic
resin. The resin was first prepared by soaking in methanol overnight followed by a series
of rinses with DI water. Approximately 300mL of broth was applied to 100mL of resin
slurry and incubated with stirring at room temperature for 1 hour. The mixture was applied
to a 250mL column and the run through was discarded. After washing the column with 1L
of DI water, the PLM products were eluted using 300mL of methanol. The eluent,
containing the active component was concentrated to dryness to give a brown residue. The
residue was suspended in 10mL of methanol: water; 40:60 and filtered. This crude extract
was purified by preparative or semi-preparative HPLC. Peaks corresponding to the various
PLMs were collected and evaporated to dryness.
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2.1.6 Characterization of PLM 1

The identity and purity of the isolated compound was confirmed by HPLC, LC-MS, MS.
1

H NMR was obtained for the isolated compound, to aid in the identification of the

compound isolated proposed to be PLM 1. MS m/z 420 [M+NH4] + and 425 [M+Na] +. The
data for 1 H NMR (chemical shifts and peaks) and for 1H- 1 HCOSY is shown in Figure 9
and Figure 10 respectively.
2.1.7 Preparation of Spore Suspension

Spore suspension were prepared in 20% glycerol or 2YT media to maintain the NP5
strain .The bacteria was allowed to grow and sporulate on SY agar for 14 days . 5mL of
water or 2YT media was added to each plate. Using an inoculating loop, the spores were
scraped off the plate and into suspension .The spore suspension was transferred using a
biosterile pipette into a sterile tube with glycerol and stored at-800 C
2.2 RESULTS AND DISCUSSlON

Analysis of the PLM biosynthetic gene cluster indicated that there are three steps of
hydroxylation ( at C-8,C-18 and C-25) after the polyketide chain is released that likely
involve the plmT4 and plmS2 genes, which encode proteins highly homologous to the
cytochrome P450 monooxygenase. PlmS2 is responsible for catalyzing hydroxylation at C18 and hydroxylation at C-8 and C-25 are most likely catalyzed by PlmT4. To better
understand the role of plmT4 gene in the PLM biosynthesis, the plmT4 gene was disrupted
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(by a previous member of the group, Nadaraj Palaniappan) to block hydroxylation in the
biosynthesis pathway. Using the fermentation and isolation method, the mutant strain, NP5
(∆plmT4∆plmS2) was fermented along with the control NP2 (∆plmS2), a PLM B producing
strain. Gene disruption of one of the tailoring enzymes, plmT4, not only results in the
abolishment of the biosynthesis of PLM B, but also allows the accumulation of two
intermediates, M-PLM1 and PLM 1 as shown in Figure 10. HPLC analyses of the
fermentation broth of this mutant reveled that as days increased, the M-PLM 1 disappeared
and after four days only PLM-1 was observed as shown in Figure 10 (A, B and C). The
malonylated lactone M-PLM 1 is unstable and undergoes decarboxylative elimination to
give the corresponding PLM 1 as shown in Figure 11. PLM 1 was purified and identified
using HPLC, MS and LC-MS spectroscopic analysis. HPLC and LC-MS analysis of the
purified compound revealed a peak eluting ~25.7 min (Figure 12 and Figure 13 ) also
consistent with the correct mass of PLM 1 ([M+NH4]+) = 420 and ([ M+Na]+) = 425).
Comparison between the acquired mass and predicted mass for PLM 1 is as shown in
Figure 14. The difference between the mass acquired for PLM 1, and the mass of the
predicted molecular formula is only m/z 0.1505. A high resolution MS measurement for
the compound was also consistent with a formula C25H38O4 for m/z 420 ([M+NH4] +) as
shown in Figure 15. The results suggests that hydroxylation at C-8 and C-25 are the first
steps in the process and catalyzed by the cytochrome P450 monooxygenase, encoded by
plmT4. The formation of M-PLM1 from the mutant suggest that malonylation process must
be occurring at an early stage , most likely preceding the release of the full length
polyketide intermediate from PLM-PKS
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Figure 10. HPLC analysis of fermentation broth of NP5

Figure 10. HPLC Analyses of fermentation broth of NP5

Figure 11. Mechanism for decarboxylation of M-PLM 1 to PLM 1
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PLM 1

Figure 12. HPLC analysis of purified PLM 1 from fermentation broth of NP5
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Figure 13. LC-MS analysis of purified PLM 1, m/z 420 and 425
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To further verify the structure of PLM, 1 H NMR of PLM 1 shown Figure 16 and 1H-1H
COSY shown in Figure 17, were carried out. PLM B 1H NMR has been previously reported
and was used in comparison with the isolated intermediate PLM 1. All of the typical peaks
of the phoslactomycin polyketide were present, which suggesting some similarity with the
isolated product. The difference between PLM 1 and PLM B is the functional group at C8 (OH in PLM B and H in PLM 1) and C 25 (NH2 in PLM B and CH3 in PLM 1). Most
peaks were assigned by comparison with the spectra of the 1H NMR of PLMB. PLM 1
spectrum was very similar to PLM-B except for the absorbance associated with a methyl
proton at position C-25 and the proton at C-8. The new peak ( a triplet) appearing at 0.87
ppm is assigned to the C-25 methyl protons. The proton absorbance were assigned using
the 1H-NMR and the 1H-1H COSY with the most significant shift listed in Table 2. The
assignment of vinyl protons at H-2 and H-3 indicates that the double bond alpha to the Cl is present in PLM 1. Detailed analyses of the 1H-1H COSY NMR spectra data shown in
Figure 17 also verified the polyketide structure by confirming the proton-proton
correlations. The data shows key proton to proton coupling, linking C4 ,C5, C6, C7, C8, C9
C10, C11 C12 and C13. The data also shows that protons on C8 are coupled to the protons at
C24. Closer examination of the spectrun also reveals that the protons at C15 are coupled to
the protons at C16. This data is consistent with the predicted PLM 1 intermediate.
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Figure 16. 1H NMR of PLM 1
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Table 1 1H NMR spectra data for PLM 1
ppm

Assignment

7.09

3-H

6.2~6.4

13, 14-H

6.00

2-H

5.72

7-H

5.67

6-H

5.33

15-H

5.41

12-H

5.11

5-H

4.95

11-H

3.90

9-H

2.48~2.55

4-H, 16-H

1.9

8-H

1.0~1.8

24-H,22-H
10-H, 17-H
18-H, 19-H
20-H, 21-H

0.87~0.91

23-H and 25-H
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Table 2 Comparison of 1 H-NMR chemical shifts for PLM 1and PLM B

Assignment

ppm PLM 1

ppm PLM B

2-H

6.00

6.09

3-H

7.09

7.09

4-H

2.55

2.55

5-H

5.11

5.11

6-H

5.67

6.04

7-H

5.72

5.97

8-H

1.9

9-H

3.90

4.28

11-H

4.95

4.95

12-H

5.41

5.41

15-H

5.33

5.33

13-H, 14-H

6.2~6.4

6.32~6.20

16H

2.55

2.48

23H

0.90

3.04

25-H

0.87

3.00
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(OH group)

Figure 17. 1H-1H COSY of PLM 1 (1)

2.3 CONCLUSION

Gene disruption of the tailoring enzyme encoded by plmT4 resulted in accumulation of
compounds lacking C-8 and C-25 hydroxyl groups. Partial characterization of the isolated
intermediate suggested that the plmT4 is likely to be responsible for C-8 and C-25 oxidation
in the phoslactomycin biosynthesis. Further characterization is required using 2D-NMR
techniques, to reveal carbon-carbon correlations and carbon-proton correlations. Together
these results will support the proposed role of the plmT4 gene in the PLM biosynthesis.
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CHAPTER 3. GENERATION OF A BLOCKED PM 1 MUTANT

3.1 INTRODUCTION

The biosynthetic gene cluster of phoslactomycin has been analyzed in detail by genetic and
biochemical investigations and genes responsible for the synthesis of the phoslactomycin
polyketide synthase have been cloned and sequenced. Studies showed that all PLM
compounds were originating from a common CHC starter unit26. The sequence analysis of
PLM biosynthetic gene cluster revealed the existence of a complete set of highly conserved
genes responsible for the formation of CHC-CoA starter unit. Genes responsible for
assembling the PLM carbon skeleton were identified and genes proposed to be involved in
post-polyketide synthase tailoring steps were proposed for example, an oxidoreductase
(plmT8) and aminotransferase (plmT1)28. The gene cluster also contains numerous other
genes involved in regulation and resistance. The role of plmT8 has been proposed, but not
experimentally determined. This chapter reports a genetic investigation of plmT8, and
partial characterization of the mutant strain lacking a plmT8 gene, in order to confirm its
role in the phoslactomycin biosynthetic pathway.
The deletion or replacement of individual genes along a biosynthetic pathway can be used
to probe the role of the genes in the biosynthesis in vivo33, 34. In this process, a particular
gene can be completely deleted or replaced with another gene that confers resistance to a
certain antibiotic such as ampicillin via PCR-targeted recombination or Red/ET-mediated
recombination 7, 35. In this study, a plmT8 gene was replaced with an ampicillin resistance
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marker. The cosmid 10B4 containing the partial phoslactomycin biosynthetic cluster was
replaced in E coli by λRED-mediated recombination, creating a gene replacement. Gene
replacement is an effective technique that takes advantage of the natural ability of an
organism to recombine homologous regions of DNA34. A gene replacement generates a
mutant inefficient or totally incapable of producing the natural product in question. The
role of a gene in the biosynthesis of the natural product is found by analyzing and
comparing the metabolite pool (intermediates or shunt metabolites) of the resultant mutant
with the wild type35. The order of steps is then determined by ordering of mutants blocked
at different steps within the pathway. This study paves the way for the elucidation of
ordering steps of the phoslactomycin biosynthesis pathway by creating a plmT8 mutant
strain (PM1) and partial characterization of generated compounds using mass spectroscopy.
The plmT8 is proposed to be an oxidoreductase. The group of oxidoreductases comprises
different types of enzymes such as oxygenases, oxidases, peroxidases, reductases and
dehydrogenases23. To date various kinds of oxidoreductases are known, which are involved
in post polyketide synthase tailoring steps23. These enzymes introduce oxygen-containing
functionalities, such as hydroxyl, epoxide, aldehyde and keto groups, or modify these
functionalities by adding or removing hydrogen atoms36. PlmT8 is proposed to catalyze
oxidation of the C-25 OH group of PLM 1, a first step in introduction of amine function.
Therefore the plmT8 mutant strain is expected to generate or accumulate PLM 2
intermediate and other possible analogues as shown in Figure 18. The proposed post-PKS
tailoring steps in phoslactomycin biosynthesis suggests that PLM 1 is the earliest
intermediate, followed by PLM 2.
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X
X

Figure 18. Proposed product of the plmT8 mutant

3.2 MATERIALS AND METHODS
3.2.1 Bacterial Strain, Plasmids and Reagents

All chemicals and solvents were purchased from Sigma or Fisher and were of a highest
grade. Yeast extract, N-Z amine type A and beef extract were obtained from Difco. Primers
for PCR were purchased from Integrated DNA Technologies (Coralville, IA). Cosmid
10B4 containing partial Streptomyces HK 803 genomic DNA and NP2 mutant strain were
kindly provided by the previous member of the group. NP2 was the wild type PLM B
producer used for generation of the PM1 mutant strain. DH5a was used as the host for
standard cloning experiments. E. coli ET12567/pUZ8002 was used as cosmid donor host
for E. coli-Streptomyces conjugation. E. coli BW25113/pIJ773 was provided by John Innes
Center (Norwich, UK) as part of the REDIRECT Technology kit SuperCos1 (Stratagene).
Platinum High Fidelity polymerase supermix was purchased from Invitrogen. All other

31

required reagents, including media, restriction enzymes, and other molecular biological
reagents were acquired from standard commercial sources.
3.2.2 Media and Culture Conditions

E. coli strains were grown in Luria broth (LB) supplemented with antibiotics apramycin
(50 μg/ml), chloramphenicol (25 μg/ml), and kanamycin (50 μg/ml) were added to the
growth media as required. Soybean mannitol agar was used for maintaining NP2 and PM1
mutant. Soybean mannitol agar supplemented with 50 μg/ml apramycin was used to
maintain the exconjugants. All growth media for Streptomyces and E. coli were prepared
according to standard protocols.
3.3 GENERATION AND ANALYSIS OF PM 1 MUTANT

3.3 1 DNA Manipulation and Construction of PM1 Mutant

The NP2 (ΔplmS2) mutant (that produces only PLM B) from Streptomyces sp. HK 803
strain was previously generated in our lab using a PCR-targeting based gene replacement
method. The ΔplmT8 ΔplmS2 (PM1 mutant) was created from the NP2 (wild type strain),
by replacing plmT8 with an aac(3)IV resistance marker and oriT cassette (which allows for
efficient transfer to Streptomyces by RP4-mediated intergeneric conjugation). The
replacement was first accomplished in cosmid 10B4 and subsequently in the chromosome
of the NP2 mutant. Cosmid 1OB4 DNA was isolated from E. coli cells using QIAprep Spin
Miniprep kit. In order to allow the integration of the 10B4 cosmid carrying the
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phoslactomycin cluster into the genome of NP2 mutant, cosmid 10B4 was first transformed
into E. coli BW25113/pIJ790 (recombination strain expressing λ-Red recombination
functions)) via electroporation according to standard protocol. A gene replacement cassette
containing aac (3)IV, oriT of RK2 and two FRT sites was amplified by using primers
containing 39nt 5' homology extension corresponding to regions flanking the target gene
and 20 nt-3' homology to the unique priming sites of the disruption cassette. Primer design
and analysis was performed using MacVector (MacVector Inc., Cary, NC) and the forward
primer:

5’-

CGGCCGCCCATGAAACGACTCGAAGGACGCAACGGCATGATTCCGGGATCCG
TCGACC-3’

and

reverse

primer

5’-

AGTGGYGTCGCCAACGGACGCGAACCGGCTCATGTAGGCTGGAGCTGCTTC3’were used (sequence homologous to the pIJ773 disruption cassette is shown in the bold,
italicized text). The allelic replacement of the plmT8 gene in the NP2 was confirmed by
PCR amplification.
3.3 2 Production of PLM analogs

The NP2 and PM1 mutants were maintained and grown in SY agar medium as shown in
Figure 19. The production of phoslactomycin was carried out as previously described, were
a loopful of spores was inoculated in 70 ml fermentation medium and incubated for 96 h
at 28 oC with shaking at 170 rpm in the dark and at the end of the fermentation period, the
cultures where harvested, the mycelia were removed by centrifugation, and the resulting
supernatant was analyzed directly by HPLC, MS and LC-MS.
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Figure 19. Growth of Streptomyces mutant strain PM1 on SY agar. Colonies appear
slightly grayish in color

3.3 3 HPLC and LC-MS analysis

A 500 μL sample of the filtered supernatant of the fermentation broth was analyzed by
using an Agilent 1100 HPLC system connected to a diode array detector. The PM broth
was analyzed with 5 μm Discovery HS C18 reverse phase column (4.6x 250 mm, Supelco,
Belefonte, PA) using a linear gradient between solvent A (acetonitrile: water; 20:80 with
0.05% formic acid) and solvent B (acetonitrile: water; 80:20 with 0.05% formic acid) from
0% to 60% over 40 minutes at a flow rate of 1.0 ml/min and detected at 235nm. The LCMS analysis was carried out using 100 of the supernatant under the same solvent and
gradient conditions, with a flow rate of 0.3 ml/min using a Surveyor HPLC system
(ThermoFinnigan) connected to a diode array detector equipped with a 2.1 μm Discovery
34

HS C18 reverse phase column (4.6 x 250 mm, Supelco). Mass spectra was collected on an
LCQ quadrupole ion trap (ThermoFinnigan) mass spectrometer equipped with an
electrospray ion source operating in positive mode.
3.4 RESULTS AND DISCUSSION

The replacement of the plmT8 gene was achieved through double crossover using
REDIRECT technology. The target gene, which was identified on the 10B4 cosmid, was
replaced by the aac(3)IV/oriT (red) cassette using PCR targeting strategies, yielding a
mutated cosmid as shown in Figure 20. Figure 21, shows the PCR product of the amplified
apramycin gene aac(3)IV oriT (red) cassette used to replace the targeted gene in the cosmid.
The mutated cosmid was introduced into E.coli ET12567/pUZ8002 by electroporation and
subsequently transferred into the target strain (NP2) by conjugation. The desired double
crossover mutants, which were selected by their apramycin-resistant and kanamycinsensitive phenotype were isolated as PM1 (∆plmT8∆plmS2) and confirmed by PCR
analysis as shown in Figure 22 (Lane 1and 2) and Lane 3-5 shows the control PCR (wild
type NP2).
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PCR product

Wild type (NP2)

1716 bp

Streptomyces
chromosome

Mutant (PM1)

1353 bp

Streptomyces
chromosome

Figure 20. (A) Flow chart of gene disruption by PCR-targeting

36

Marker

Marker

Lane

1

2

Figure 21. (A) Apramycin gene aac(3)IV/oriT (red) cassette
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Marker

Marker

Lane 1

2

3

4

5

Figure 22. PCR confirmation analysis

The PM1 (∆plmT8∆plmS2) mutant was fermented and processed along the wild. Analysis
of fermentation broth revealed a peak eluting ~20.7 min in the total ion chromatogram (TIC)
that had a m/z of 583 as shown in Figure 23, consistent with the formation of M-PLM 2
([M-H+2Na]+). The addition of mild base to the PM1 fermentation broth resulted in the
disappearance of this peak, consistent with our prediction of a malonylated product.
Addition of a base will cause deprotonation of the malonyl group facilitating
decarboxylative elimination reaction and the formation of corresponding product without
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a malonyl group. Analysis of the purified broth also revealed peaks with m/z 515 ([M+H]
+

), 532 ([M+NH4] +) and m/z 537 ([M+Na] +) as shown in Figure 24, consistent with the

mass of the PLM 2 P compound. Analysis of the PM1 mutant also revealed a peak eluting
at 6.2 min in the total ion chromatogram (TIC) that had a m/z of 453 and 475, consistent
with the formation of PLM 2 with hydrolyzed lactone, ([M+H]+) and ([M+Na]+)
respectively. A high resolution MS analysis of the filtered broth was consistent with
formation of PLM 2 with a hydrolyzed lactone as shown in Figure 25.
The observation of mass consistent with the formation of M-PLM 2, PLM 2 and PLM 2 P
products in PM1 mutant suggests the proposed role of plmT8 as an oxidoreductase. The
observation M-PLM 2 in the plmT8 deletion mutant strain suggest that malonylation is
likely to occurs in the early stage, indicating that modification steps can occur on an
intermediate with a C-3 malonyl group attached. Decarboxylation elimination by PlmT2 is
likely to occur later in the post-PKS modification steps of phoslactomycin. The observation
of phosphorylated products in the plmT8 mutant strain suggests that the proposed
phosphorylation catalyzed by PlmT5 kinase can occur early in the step in the
phoslactomycin pathway. The accumulation of PLM 2 products also supports that plmT4
is responsible for addition of the C-8 and C-25 hydroxyl groups, since the mass obtained
are consistent with oxidation at C-8 and C-25 (PLM 1).
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Figure 23. LC-MS analysis of purified PM1 broth, m/z 583
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Figure 24. ES+ MS analysis of filtered of PM1 fermentation broth,
m/z 515, 532 and 537
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Figure 25. ES+ MS analysis of filtered of PM1 fermentation broth, m/z 453 and 475

Some of the key drawbacks to continued partial analysis include low fermentation titers
and various analogues produced in the fermentation. Cloning of the PLM biosynthetic gene
cluster and creation of a PM1 mutant sets the stage for isolation of the more gene product
of the PM1 mutant and then NMR characterization will be possible.
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CHAPTER 4. HETEROLOGOUS EXPRESSION OF TAILORING ENZYMES

4.1 INTRODUCTION

The enzymological phase of polyketide biosynthesis research started in the 1990’s when
the first crude cell extracts fractionations and in vitro characterizations were carried out.
Amongst the first post-PKS tailoring enzymes to be isolated and studied was carminomycin
4-O-methyltransferas37. It was partially purified from the wild type producer Streptomyces
sp. strain37. In order to study and characterize individual enzymes participating in the
biosynthesis of a polyketides, for example studying substrate specificity in vitro and a
detailed kinetic analysis, their respective genes needs to be expressed in a heterologous
host such as E.coli, followed by enzyme purification38. Successful production of proteins
requires the success of three individual factors: expression, solubility and purification39. E.
coli remains the most used host for recombinant protein expression because it is easy to
manipulate and cheap40. A variety of high-level expression vectors are now available to
allow gene expression under the influence of the bacteriophage T7 polymerase promoter41.
The development of the His-Tag technology allows the fusion of six histidine amino acid
residues to either the N- or C-terminal end of the expressed protein which facilitates the
purification of the recombinant protein by affinity chromatography using metal chelation
resins42. Additional residues or tags can be engineered on either N-terminal or C-terminal
end of the protein of interest during cloning, tags can confer the advantage of increased
yield, by providing a reliable context for efficient translation initiation, enhancing
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solubility of expressed proteins42. A common limitation of recombinant protein production
in bacteria is the formation of insoluble protein aggregates known as inclusion bodies. One
possibility to avoid inclusion bodies is to use large affinity tags43. The biochemical features
of different tags influence the stability, solubility and expression of proteins to which they
are attached. In other words, using expression vectors that include a fusion tag facilitates
recombinant protein solubility44. A disadvantage is, however, that proteins with these tags
cannot be purified with a specific affinity matrix. The fusion construct must be used in
combination with a small affinity tag for purification45. Elution of the bound enzyme is
readily achieved by changing parameters such as salt concentration or pH.46 After
purification, the proteins can be used in a number of assays depending on the reactions they
catalyze to monitor the substrate specificity as well as the rate by which they catalyze their
reactions. The in vitro assays using expressed enzymes provide greater and more valuable
insight into the mechanistic role of the individual enzyme in the biosynthetic process as a
whole.
The final enzymes involved in phoslactomycin post-polyketide synthase tailoring steps
have already been characterized. The enzymes studied are PlmT2, PlmS2 and PlmS3 as
described in the introduction chapter and the enzymes were characterized by carrying out
detailed in vitro enzyme assay.
This chapter we describe the cloning, expression and purification of the initial post-PKS
tailoring enzymes in the phoslactomycin biosynthesis. The proposed tailoring enzymes for
this work in are, PlmT4 a cytochrome P450 monooxygenase, PlmT5 a kinase and PlmT8,
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an oxidoreductase10. Expression and purification of these enzymes will pave the way for
in vitro enzyme characterization methods and protein crystal structure determination (if
needed) leading to analysis of the role of each proposed enzyme. This will lead the way for
elucidation of the ordering steps of the post-polyketide synthase tailoring steps in the
phoslactomycin pathway.

Scheme 1. Proposed ordering of the post-PKS tailoring steps in PLM pathway

The enzymes studied in this work, also commonly found occurring in post-PKS tailoring
reactions are briefly discussed in the following section.
4.1.1 Plm T4, a cytochrome P450 monooxygenase

The plmT4 gene is proposed to be a cytochrome P450 monooxygenase. CYP450s belong
to a very large and diverse family containing heme as a cofactor (hemeproteins).
Cytochrome P450 (CYP450) proteins, named for the absorption band at 450 nm of their
carbon monoxide bound form, are one of the largest superfamilies of enzyme proteins47.
There is also a broad versatility of reactions catalyzed by cytochromes P450 such as carbon
hydroxylation, heteroatom oxygenation, dealkylation, epoxidation, aromatic hydroxylation,
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reduction, and dehalogenation48. In several instances, monooxygenases activity, arises
from induction of CYP450 and associated ferredoxin or of a CYP450 only. CYP450 plays
two main roles in living organisms namely catalyzing oxidation steps in the biosynthesis
of compounds like steroids and detoxification of xenobiotics compounds, facilitating their
elimination from living organisms49. CYPs have been proposed to be involved in the
biosynthesis of phoslactomycin29. To date various kinds of CYPs, are known, which are
involved in post-PKS modifications and understanding of CYP450 is essential for efficient
engineering of Streptomyces strains capable of generating novel antibiotics. For example,
approaches that utilize substrate promiscuity of CYP450s have been applied to generate
novel analogues of erythromycin and pikromycin50. The proposed CYP-dependent
hydroxylation (C-8, C-18 and C25) in the post-PKS tailoring steps of PLM, are proposed
to be carried out by PlmS2 and PlmT4. The work on PlmS2 has already been completed and
published by the previous member of the group, this work focus on cloning, expression,
purification of PlmT4, and partial characterization of the enzyme (in vitro enzyme assay).

4.1.2 Plm T5, a kinase

A kinase is an enzyme that adds phosphate group to other molecules and these enzymes
are key regulators of cell function51. Kinases which are involved in post-PKS modification
have been studied, for example, a kinase involved in the biosynthesis of a polyketide
known as fostriecin25,

22.

. Fostriecin is a unique phosphate monoester antibiotic that was

isolated from Streptomyces pulveraceus and is structurally related to phoslactomycin52.
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Homology analysis showed that fosH shares 43% sequence identity with PlmT5 and was a
kinase, based on an enzyme activity assay performed in vitro. A FosH heterologous
expression system was constructed on pET28b and introduced into E. coli BL21 to produce
the target protein. The results obtained supported the hypothesis that FosH is responsible
for the phosphorylation of fostriecin22. In this study we focused on cloning, expressing and
purifying PlmT5, a putative kinase. This work will pave the way for in vitro enzyme assays
so that the PlmT5 role in phoslactomycin biosynthetic pathway is confirmed.

4.1.3 Plm T8, an oxidoreductase

Several types of enzymes have been reported to be involved in post-PKS modifications
catalyzing different chemical reactions28,53. The group of oxidoreductases comprises
different types of enzymes such as oxygenases, oxidases, peroxidases, reductases and
dehydrogenases36. These enzymes introduce oxygen-containing functionalities, such as
epoxide, aldehyde and keto groups, or modify these functionalities by adding or removing
hydrogen atoms, for example, transforming a ketone into a secondary alcohol or an
aldehyde into a carboxylic acid36. All of these reactions have an impact on the stereoelectronic and physico-chemical properties of the substrates, by creating or removing chiral
centers, introducing highly reactive functional groups, such as aldehydes or epoxides,
changing the solubility of a molecule or converting hydrogen bond donors. PlmT8 is
proposed to transform the C-25 OH group into an aldehyde as shown in scheme 2 below.
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Scheme 2. Proposed PlmT8 reaction
4.2 MATERIALS AND NETHODS

4.2.1 Materials

Buffers, salts and reagents were of highest quality grade and were purchased from Sigma
(St. Louis, MO) unless otherwise noted. Dithiothreitol (DTT), isopropyl-β-D-thiogalactopyranoside (IPTG), kanamycin sulfate, β-NADPH (β- Nicotinamide adenine dinucleotide
phosphate), β-NADP+ and ampicillin were purchased from RPI Corporation (Chicago, IL).
Nickel-nitrilotriacetic acid agarose (Ni2+-NTA agarose) was purchased from Qiagen
(Valencia, CA). Plasmid Mini-Kits were from Fermentas (Glen Burnie, MD). All reagents
for sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and 10%
acrylamide/Tris-HCl precast gels were purchased from BioRad. SDS-PAGE analysis was
carried out using 12% gels and visualized with Coomassie Brilliant Blue. DNA sequencing
was carried out at the DNA sequencing core facility at Oregon Health and Sciences
University (OHSU), Portland, OR. The LIC cloning kits containing the pET44a plasmid
was from Novagen. Restriction endonucleases and T4 DNA ligase was purchased from
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New England Biolabs (Ipswich, MA). PCR primers were custom synthesized from
Integrated DNA Technologies (Coralville, IA). PCR reactions were carried out with the
GC Rich PCR System from Roche (Basel, Switzerland).
4.2.2 Bacterial strains, plasmids, and growth conditions

Luria-Bertani (LB) medium was used for growth of bacteria. The following antibiotics
were added to the media when necessary: kanamycin (50 g/ml), carbenicillin (100 g/ml),
chloramphenicol (20 g/ml), streptomycin (25 g/ml), and phleomycin (50 g/ ml).

4.2.3 DNA manipulation

DNA restriction and modifying enzymes were used as recommended by the manufacturer
(New England Biolabs). Standard protocols were used for recombinant DNA techniques
(Sambrook). DNA fragments were purified from agarose gels with the QIAquick
purification kit (QIAGEN). Plasmids were prepared using a QIAprep spin miniprep kit
(QIAGEN). Deep Vent DNA polymerase was used in all PCRs according to the supplier’s
instructions (New England Biolabs).
DNA sequencing was performed at the MMI core facility and at Primate Center, Oregon
Health and Sciences University (Portland, OR). Primer design and analysis of DNA
sequences was performed using MacVector (MacVector Inc., Cary, NC) and Accelrys DS
gene (Accelrys Inc., San Diego, CA) software.
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4.2.4 Instrumentation

PCR was carried out on a Gene Amp PCR system 2400 from PerkinElmer Life Sciences.
UV-Vis spectroscopy was performed with UV Shimadzu 1600. Centrifugation was carried
out on an Avanti J- 20 centrifuge, an LE-80K Ultra centrifuge using a Ti-60 rotor, and a
Model TJ 6 swinging bucket centrifuge, all from Beckman Coulter, Inc. SDS-PAGE was
carried out on a mini Protean III from BioRad.

4.2.5 Cloning, Expression and Purification of PlmT4 Protein

The plmT4 gene was amplified from genomic DNA via PCR and cloned with either N- or
C-terminal

His6-fusions

using

CATATGTCACAGCTCTCGTCC-3

the

following
and

primers
reverse

forward

primer

primer,

5’5’-

AAGCTTTCACCACGTGACGGG-3’. The primers contained the restriction sites
(underlined) for NdeI and HindIII to allow directional cloning into a pET28a vector.
Amplification of the gene for construction of the N-terminal fusion was followed by
restriction digestion of the PCR product with NdeI/HindIII, gel purification (1% agarose),
and ligation into NdeI/HindIII digested pET28a using T4 DNA ligase to give pET28aplmT4. Plasmid DNA was isolated from all the constructs and the primary structure of the
genes confirmed by sequencing. The plasmids containing plmT4 were transformed into E.
coli BL21 (DE3) for expression of recombinant proteins. Cultures of transformed cells were
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grown at 37 ˚C in LB/kan with shaking (250 rpm) until an OD600 of 0.9 was obtained,
IPTG was added to a final concentration of 0.25 mM, and the cells were grown for an
additional 4½ hours. The cells were collected by centrifugation at 7,500g for 15 minutes at
4 ºC. The cells were stored at -80 ºC until needed. Frozen cell paste was suspended to 250
mg/mL in 50 mM HEPES (pH 7.0), 0.75 M NaCl, 2 mM βME, and 1 mM PMSF.
Lysozyme was added to a final concentration of 250 µg/mL and the cells incubated at 37
˚C for 30 minutes, followed by 3 intervals of freeze thaw cycles. The cell lysate was
centrifuged at 26,000g for 30 minutes at 4 ˚C, and the cell-free extract recovered and
filtered (0.45 µm MCE). The CFE was loaded onto a column containing Ni2+-NTA agarose
equilibrated in lysis buffer, and washed with 10 volumes of lysis buffer containing 25 mM
imidazole. The protein was eluted with 250 mM imidazole in lysis buffer without. The
eluant was concentrated to 2 mL using the Amicon Ultra YM-10. The fractions containing
pure protein were pooled, exchanged with 50mM sodium phosphate buffer pH 7.2 and
stored in 20% glycerol at -80 oC.

4.2.6 Cloning, Expression and Purification of PlmT5 Protein

The plmT5 gene corresponding to a kinase was amplified from genomic DNA via PCR and
cloned with N –terminal using the following primer, forward primer 5’CATATGTATGTCGCCAAGTGC-3’ (NdeI restriction site) and reverse primer, 5’AAGCTTTCACTCGTACTGGCG-3’ (HindIII restriction site), Amplification of the gene
for construction of the N-terminal fusion was followed by restriction digestion of the PCR
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product with NdeI/HindIII, gel purification (1% agarose), and ligation into NdeI/HindIII
digested pET28a using T4 DNA ligase to give pET28a-plmT5. The coding region of plmT5,
was also amplified by primers were, 5’-GACGACGACAAGATGTATGTCGCCAA-3’,
5’GAGGAGAAGCCCGGTCACTCGTACTG-3’.The 5’ end of the primer incorporated
ligation-independent cloning (LIC) sequences. The amplified product was ligated into the
vector pET-44 Ek/LIC after being treated with LIC-qualified T4 DNA polymerase. Primers
for amplification of plmT5 were designed for subsequent LIC cloning in pET44a with an
N-terminal NusA Tag. Amplification of the gene was followed by the insertion of the PCR
products into pET44a following the manufacturer's instructions to give pET44-plmT5. To
analyze expression of the plmT5 genes cloned in pET28a and pET44a, cultures of
transformed BL21 (DE3) were grown overnight in tubes containing LB medium and
appropriate antibiotics. Cultures were diluted 1:50 and grown at 37°C to mid-log phase
(0.4 to 0.6 OD600 unit/ml). Gene expression was induced with 0.5 mM IPTG (isopropylD-thiogalactopyranoside), and cultures were grown for 6 h at the same temperature. Cells
were harvested by centrifugation at 12,000 g for 20 min, at 4 oC. The E. coli cell pellets
were suspended in lysis buffer (50mM sodium phosphate buffer pH 7.2, 300mM NaCl,
5mM 2-mercaptoethanol, 10% glycerol, 0.05% (v/v) Tween-20) with 10 mM imidazole
and lysozyme (1 mg mL-1). The resulting cell suspension was incubated on ice for 30 min
and cell lysate was cleared by centrifugation at 16,000 g for 20 min. For the protein cloned
in pET28a, the crude cell extract was loaded onto a Ni-NTA resin column. His-tagged
protein was eluted by using buffer-A with 300 mM imidazole. The purified protein was
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analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and
visualized by staining with Coomassie blue
4.2.8 Cloning, Expression and Purification of PlmT8 Protein

The gene plmT8 was amplified from 10B4 cosmid. To amplify plmT8, the following
primers 5’-CATATGGCTAAGCGCTTCTCCACCATC-3’ (NdeI restriction site) and
reverse primer, 5’-AAGCTTTCAGAGCTCGTGGTTCCGGAG-3’ (HindIII restriction
site were used. The plm genes were cloned into expression vector pET28a to construct the
plasmid pET28-plmT8. The plmT8 gene was also cloned into pET44 a vector using the
same procedure described previously. The generated plasmids named pET-8a-plmT8 and
pET-44-plmT8 were then transformed into E.coli strain BL21 (D3) cells and the positive
clones were confirmed by DNA sequencing. All plasmids were used to transform E. coli
BL21 (DE3) cells. The resulting transformants were grown at 37 oC in LB medium
containing either 50 µg mL-1 kanamycin (for pET28a transformants) or 100 µg mL-1
ampicillin (for pet44) to an A600 = 0.6, induced with 0.1mM isopropyl-β-Dthiogalactopyranoside, and incubated overnight. Cells were harvested by centrifugation at
12,000 g for 20 min, at 4 oC. The appropriate E. coli cell pellets were suspended in lysis
buffer. A (50mM sodium phosphate buffer pH 7.2, 300mM NaCl, 5mM 2mercaptoethanol, 10% glycerol, 0.05% (v/v) Tween-20) with 10 mM imidazole and
lysozyme (1 mg mL-1). The resulting cell suspension was incubated on ice for 30 min and
cell lysate was cleared by centrifugation at 16,000 g for 20 min. The crude cell extract was
loaded onto a Ni-NTA resin column. The PlmT8 protein was eluted by using buffer-A with
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300 mM imidazole. Fractions containing pure protein were pooled, exchanged with 50 mM
sodium phosphate buffer pH 7.2 and stored in 20% glycerol at -80 oC.
4.2.9 Conversion of PLM 1 to PLM 2 in vitro

The gene plmT4 encodes a cytochrome P450 monooxygenase (CYP450). The enzyme is
likely to be responsible for C-8 and C-25 hydroxylation of the PLM PKS product. We
believe that PLM 1, is one the first intermediates and a substrate for PlmT4. Enzymatic
conversion of PLM 1 to PLM 2 was be monitored by HPLC assy. The purified plmT4 (0.3
μM) was incubated in a conversion buffer with PLM 1 (100 μM), spinach ferredoxin (50
μg), ferredoxin NADP reductase (0.1 U), NADP (1 μmol), NADPH+ (1 μmol), glucose-6phosphate (10 μmol) and glucose-6-phosphate dehydrogenase (1 U) in a reaction volume
of one ml at 30 oC for 30 minutes. NADP+, glucose-6-phosphate and glucose-6-phosphate
dehydrogenase will be added as an “NADPH regenerating system. Simultaneous enzyme
and substrate controls were run. An aliquot of reaction was be injected on HPLC to detect
PLM 2 formation. The identity of PLM 2 was assayed by mass spectrometry.
4.3 RESULTS AND DISCUSSION

4.3.1 Characterization of the CYP450 in vitro by heterologous expression in E.coli

To investigate the function of PlmT4 in the PLM biosynthesis pathway, an enzyme activity
assay was performed in vitro.

First, a PlmT4 heterologous expression system was

constructed on pET28a and introduced into E.coli BL 21 to produce target protein .The
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expression plasmid was confirmed by sequencing and the target protein was purified as
descried in the experimental procedures and analyzed by SDS-PAGE analysis. The SDSPAGE analysis revealed the presence of a significant quantity of a soluble protein of 46
kDa (Figure 26 lane7-9), which was consistent with the predicted molecular mass of plmT4
(44 kDa) and the hexahistidine tag (2 kDa). This band was absent in the control culture.
PlmT4 was purified as a His-tagged protein by affinity chromatography on a Ni-NTA
agarose column. The typical yields of purified PlmT4 were 408-600µg/mL.
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Figure 26. (A) SDS-PAGE of purified PlmT4 protein
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The eluted PlmT4 protein was brick red in color (Appendix Figure 34A). The term P450 is
derived from the spectrophotometric peak at the wavelength of the absorption maximum
of the enzyme (450nm) when it is in the reduced state and complexes with CO. The UVvisible absorption spectrum of the spectrum of the purified protein shows a characteristic
390 to 450nm CYP spectrum (Figure 27). The absorbance increased as the concentration
of increased, as shown in Figure 27

[Increasing concentration]

Figure 27. UV-Visible absorption spectrum of purified PlmT4
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The recombinant PlmT4 was shown to catalyze a complete conversion of PLM 1 to PLM
2 as shown in Figure 28. It is noteworthy that the hydrolyzed-PLM 2 product was observed
under these reaction conditions, this lactone likely opens under basic conditions. The MS
for PLM 1 only is shown in Figure 29. The likely identity of PLM 2 was assessed by MS
and the analysis revealed that the new product, m/z of 453 and 475 as shown in Figure 30,
consistent with the addition of two oxygen atoms to PLM 1. Control reaction is shown in
Figure 31. This result supports the hypothesis that PlmT4 is likely to be responsible for the
hydroxylation of C-8 and C-25.

m/z, 441.24 and 425.27

m/z, 453.35 and 475.33

Figure 28. In vitro conversion of PLM 1 to PLM 2
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Figure 29. ES+ MS analysis of purified of PLM 1, m/z 425 and 441
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Figure 30. ES+ MS analysis of PLM 1 conversion reaction,m/z 453 and 475
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Figure 31. ES+ MS analysis of the enzyme control reaction (without enzyme), m/z 441
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4.3.2 Purification of PlmT8

The 1716 bp plmT8 ORF was cloned into prokaryotic expression vector pET28a and PlmT8
was expressed as a soluble N-terminal polyhistidine tagged protein in E. coli
ArcticExpressTM (DE3) cells. ArcticExpressTM competent cells are engineered to address
the common bacterial gene expression hurdle of protein insolubility and competent cells
have been engineered for improved protein processing at low temperatures. SDS-PAGE
analysis of cell extracts grown under IPTG induction conditions revealed the presence of a
significant quantity of a soluble protein of 62 kDa, which was consistent with the predicted
molecular mass 61 kDa of PlmT8 (Figure 32 lane 7). This band was absent in the control
culture.
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Figure 32. SDS-PAGE of purified Plm T8 protein

4.3.3 Purification of PlmT5

PlmT5 was expressed as a fusion protein. The final pET-44-plmT5 construct was able to
express the recombinant protein as fusion protein with fusion tag consisting of the NusA
protein, polyhistidine and S-peptide. The Nus-A protein increases the proportion of the
soluble protein when expressed as a fusion partner. After induction of IPTG E.coli BL21
(D3) transformed with pET44-plmT5 produces a fusion protein of approximately which
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contained a Nus-His-Tag of 57.8 kDa. With the fusion tag, the expressed plmT5 protein
can be purified by either Ni2+ or S-protein affinity chromatography. Both Ni-NTA and Sprotein affinity chromatography were applied for the purification of pET44-plmT5. The
size of the fusion matched well with its theoretical weight which is 88kDa (Lane 1).
Meanwhile the pET-44-plmT5 was also engineered to express an enterokinase and a
thrombin cleavage site so that the encoded fusion sequence can be removed from the
purified PlmT5 protein The target protein PlmT5 was easily released from S-protein agarose
following digestion with a substantial quantity of thrombin, which appeared as a single
band on SDS-PAGE with a mass consistent with the theoretical weight of 25 kDa as shown
in Figure 33 (lane 4- 6)
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CHAPTER 5. CONCLUSION AND FUTURE DIRECTION

5.0 CONCLUSION AND RECOMMENDATION FOR FUTURE WORK

The phoslactomycin gene cluster consists of 29 ORFs encoding seven modular type 1
polyketide designated (plm1 through plm 7) and tailoring enzymes28. Structurally, the
natural phoslactomycin has varying functionalities that are absent from the molecule
generated from PKS, including three hydroxyl groups at C-8 and C-18 positions, a
phosphoryl group at C-9, an amine group at C-25 and an unsaturated bond at the C2-C3
site. After PKS elongation and liberation from PKS by the TE enzyme, the nascent PKS
chain undergoes some or all of the normal post-polyketide synthase tailoring steps that are
typically associated with phoslactomycin natural product such as hydroxylation,
phosphorylation and others. The work presented in this thesis describes the initial postPKS tailoring steps in the biosynthesis of phoslactomycin. It also provides valuable insights
into the in vivo roles of key enzymes involved in the biosynthesis of phoslactomycin.
The first steps of the post-PKS tailoring steps in the phoslactomycin pathway were
analyzed using in vivo or in vitro analyses of selected genes by targeted gene replacement
and enzyme activity assays. The observation of M-PLM 1 and M-PLM 2 from the plmT4
and plmT8 deletion mutants suggest that the malonic acid is linked to the PKS chain at the
last module of plm cluster (module 7) during PKS elongation, most likely it precedes the
release of the full length polyketide intermediate from PLM-PKS. The observation of
malonylated products also suggests that modification steps can occur on an intermediate
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with a C-3 malonyl group on it, suggesting that decarboxylation elimination by PlmT2 is
likely to occur later in the post-PKS modification steps of phoslactomycin. The cis-∆2, 3
double bond formation might even be the last step in the post-PKS tailoring of
phoslactomycin biosynthesis to yield phoslactomycin. At this point, when or how the
malonylation occurs in the PLM biosynthetic process remains a mystery. Future work is
required to unveil this mystery.
The isolation of PLM 1 from the plmT4 mutant strain indicates that PLM 1 is likely to be
the first intermediate and a substrate of PlmT4 enzyme. This enzyme is the only other P450
monooxygenase encoded by the phoslactomycin biosynthetic gene cluster. Based on gene
replacement and in vitro enzyme activity assay, Plm T4 is likely to be responsible for C-8
and C-25 hydroxylation of the PLM-PKS product. Further characterization of the isolated
intermediate is needed using spectroscopic analyses such as 2D NMR to further confirm
the linking of carbon to carbon bonds and carbon to protons bonds. For example the 2D
HSQCED spectra of PLM 1 will confirm how the protons are attached to carbons. PLMs
were first identified based on their potent antifungal activity against a range of
phytopathogenic fun. The potent activity of the isolated intermediate PLM 1 can also be
tested. Activities against Aspergillus oryzae, Pyricularia oryzaei and Aspergillus fumigatus
is worth reporting in future.
The accumulation of the several PLM 2 products in the plmT8 mutant strain suggested that
plmT8 gene is likely to be responsible for the oxidation of the C-25 hydroxyl group to the
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corresponding aldehyde. Further work includes isolating the observed intermediates and
characterization using NMR and carrying out in vitro enzyme assays.
The observation of phosphorylated products in the plmT8 mutant strain suggests that the
proposed phosphorylation catalyzed by PlmT5 kinase can occur early in the step in the
phoslactomycin pathway. Future work includes studying and analyzing the product profile
of the plmT5 mutant strain to further analyze the stage at which phosphorylation occur in
the pathway.
The tailoring enzymes expressed and purified in this study also sets the stage for
determining the ordering steps of the post-PKS tailoring steps. The enzyme are used for
characterization of the pathway by carrying out detailed in vitro enzyme assays, like
determining reaction rates of isolated intermediate with proposed substrates, understanding
and analyzing substrate specificity as well. Other studies that can be done using the
enzymes if necessary is carrying out x-ray crystallography. This will provide a more
comprehensive understanding of the interaction of proteins with the substrates. Tailoring
enzymes also presents another variable that can impact structural diversity in modular PKS.
So studying the enzymes may offer an opportunity to modify the structure of existing
natural product based drugs to improve their activity, stability and pharmacokinetic
properties.
The results obtained in this study pave the way for the complete elucidation of the postPKS tailoring steps in the phoslactomycin biosynthesis pathway. It is worth mentioning
that the ordering steps may not be absolute, there may be parallel pathways, and for
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example phosphorylation and decarboxylation elimination may occur on several
intermediates. The data obtained in this study sets the stage for understanding the
mechanisms that build these structurally unique and pharmaceutically important agents and
contributes to the general field of combinatorial biosynthesis.
.
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7.0 APPENDIX

Figure 34 A. Purified PlmT4 protein
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